CheckMate 648 Update: Phase III Study of First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT for Advanced Esophageal Squamous Cell Carcinoma

Source: CCO Independent Conference Highlights of the 2023 ASCO Gastrointestinal Cancers Symposium*
Download Slideset
January 19-21, 2023; San Fransico, California
With 29 months of follow-up, both nivolumab + chemotherapy and nivolumab + ipilimumab continued to demonstrate clinically meaningful OS benefit compared with chemotherapy alone in previously untreated patients with advanced esophageal SCC.
Format: Microsoft PowerPoint (.ppt)
File Size: 121 KB
Released: February 2, 2023

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Incyte Corporation
Merck Sharp & Dohme Corp.
Seagen Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings